RxDoctor Payments Data

Gary Miller, MD

Internal Medicine · Canton, CTNPI 1528027430

Payments from drug & device makers

$636in general payments, 2019–2025

Across 20 payments — averaging $31.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$154
  • Sanofi-aventis U.S. LLC$124
  • Smith+Nephew$114
  • Neurocrine Biosciences, Inc.$58
  • Otsuka America Pharmaceutical, Inc.$36
  • Harmony Biosciences LLC$31
  • plus $119 from 6 others

What the payments were for

  • Food & beverage$46897%
  • Entertainment$143%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$636 in reported general payments places this provider in the 70th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$122,590
Medicare patients
518
Services billed
965

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,969$511,008
XareltoRivaroxaban737$204,880
NuplazidPimavanserin Tartrate96$171,126
IngrezzaValbenazine Tosylate19$146,099
JardianceEmpagliflozin434$126,593
XifaxanRifaximin75$108,784
JanuviaSitagliptin Phosphate359$98,471
TrulicityDulaglutide128$96,536
LinzessLinaclotide118$69,302
OzempicSemaglutide65$68,801
Trelegy ElliptaFluticasone/Umeclidin/Vilanter101$52,586
MyrbetriqMirabegron257$49,108
TradjentaLinagliptin192$45,009
EntrestoSacubitril/Valsartan105$36,361
FarxigaDapagliflozin Propanediol126$35,944

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$58$146,09919 claims
AbbVieLinzess, Restasis$19$93,966165 claims
AstraZenecaFarxiga$22$35,944126 claims
Otsuka America Pharmaceutical, Inc.Rexulti$36$31,93644 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Canton

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →